Aethlon Medical Inc. Unveils Corporate Presentation Highlighting Hemopurifier® Blood Purification Device and Breakthrough Designations
Reuters
Aug 21
<a href="https://laohu8.com/S/AEMD">Aethlon Medical Inc</a>. Unveils Corporate Presentation Highlighting Hemopurifier® Blood Purification Device and Breakthrough Designations
Aethlon Medical Inc. has released a corporate presentation highlighting the advancements and strategic initiatives surrounding its Hemopurifier® blood purification device. The presentation outlines the Hemopurifier's patented technology, which has demonstrated efficacy in clearing enveloped viruses and extracellular vesicles (EVs) in early clinical trials. The device has received two FDA "Breakthrough Device" designations for its potential use in treating advanced/metastatic cancer and life-threatening viral infections without approved therapies. Aethlon is actively engaged in oncology trials in Australia and R&D for Long COVID, supported by a broad patent portfolio and Australia's R&D rebate program. The Hemopurifier, with its unique mechanism of action, is designed to target multiple therapeutic pathways in oncology and infectious diseases. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief on August 20, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.